Abstracts

Claire K. Mulvey, Claire Hooker, Jennifer A. Chan, Rahul Raj Aggarwal, Pelin Cinar, Thomas A. Hope, K. Pallav Kolli, Li Zhang, Susan Calabrese, Jennifer A. Grabowsky, Diane Reidy-Lagunes, Lawrence Fong, Nitya Prabhakar Raj, Emily K. Bergsland

pdf (2.24 MB) pdf Download Poster (2.24 MB)

T4 - A Pilot Phase 2 Study of Albumin-Bound Rapamycin Nanoparticles, ABI-009, in Patients with Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors (NETs) of the Lung or Gastroenteropancreatic System

Published in 2018 Listed under Poster, T

Download

Abstract ID: 63

Robert A. Ramirez, Marc Matrana, Suma Satti, Ryan P. Griffin, Ramcharan Thiagarajan, J. Philip Boudreaux, Eugene A. Woltering

pdf Download Poster (385 KB)

[T10] Kennecke - Phase Ib trial of cabozantinib (Cabometyx®) combined with Lu-177 DOTATATE radioligand therapy in patients with advanced, somatostatin receptor positive NETs.

Published in 2023 Listed under T

Download

[T10] Mohamed - Pilot Study of TQ Formula in Combination with Nivolumab and Ipilimumab in Metastatic Gastroenteropancreatic Neuroendocrine Carcinomas (GEP-NECAs)

Published in 2022 Listed under T

Download

[T11] Chauhan - NET RETREAT: a Phase II Study of 177Lutetium-Dotatate Retreatment vs. Everolimus in Metastatic/Unresectable Midgut NET

Published in 2023 Listed under T

Download

[T12] Mailman - Neuroendocrine tumors AI-based clinical trial search tool eases clinical trial discovery for patients and health care professionals

Published in 2023 Listed under T

Download

[T1] Hope - ACTION-1: A randomized Phase Ib/3 trial of RYZ101 compared with SoC in SSTR+ well-differentiated GEP-NET with progression following Lu-177 SSA

Published in 2023 Listed under T

Download

[T1] Paulson - Phase 2 study of nab-sirolimus in patients with well- differentiated and advanced/metastatic neuroendocrine tumors of the gastrointestinal tract, lung, or pancreas

Published in 2024 Listed under T

Download

[T1] Stockton - Phase Ia/Ib Study of BAY1895344 Plus Topoisomerase I Inhibitors with a Focus on Poorly Differentiated Neuroendocrine Carcinomas and Pancreatic Adenocarcinoma

Published in 2022 Listed under T

Download

[T2] Demeure - Phase 2 study of nab-sirolimus in patients with welldifferentiated and advanced/metastatic neuroendocrine tumors of the gastrointestinal tract, lung, or pancreas

Published in 2023 Listed under T

Download

[T2] Halfdanarson - COMPOSE: Pivotal Phase III Trial for Well- Differentiated Aggressive Grade 2/3 Gastroenteropancreatic Neuroendocrine Tumors Comparing 177Lu-edotreotide with Best Standard of Care

Published in 2022 Listed under T

Download

[T2] Luria - KinLET: Phase I Trial for Dose Determination and Pharmacokinetics Evaluation of [177Lu]Lu-edotreotide Radiopharmaceutical Therapy in Pediatric Participants with SSTR+ Tumors

Published in 2024 Listed under T

Download

[T3] Chauhan - Phase 2 Study to Evaluate the Safety, Pharmacokinetics, and Dose Response of Paltusotine Carcinoid Syndrome

Published in 2022 Listed under T

Download

[T3] Dolkar - Phase 2 Dose Optimization Trial of Everolimus post Bland Hepatic Artery Embolization (Evero-Embo) in patients with Neuroendocrine Tumors

Published in 2024 Listed under T

Download

[T3] Lin - Phase 1/2 Trial of Pb-212-VMT-alpha-NET in GI Neuroendocrine Tumors and Pheochromocytoma/ Paraganglioma Previously Treated with Radioligand Therapy

Published in 2023 Listed under T

Download

[T4] D'Souza - Lipiodol Deposition in NET Liver Metastases during TACE using Pressure-Enabled versus Endhole Catheters: Pilot Data from a Randomized, Internally-Controlled Trial

Published in 2024 Listed under T

Download

[T4] Iyer - Phase 2, Multicenter, Open-label Basket Trial of nab-Sirolimus for Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1/2 (PRECISION I)

Published in 2023 Listed under T

Download

[T4] McGarrah - Phase 1-2 Trial of Vesicular Stomatitis Virus Expressing Human Interferon-β and NIS (VSVIFNβ- NIS), with Pembrolizumab, in Patients with Neuroendocrine Carcinoma

Published in 2022 Listed under T

Download

[T4] Poster - D'Souza - Lipiodol Deposition in Neuroendocrine Tumor Liver Metastases during TACE using Pressure-Enabled versus Endhole Catheters: Pilot Data from a Randomized, Internally-Controlled Trial

Published in 2024 Listed under Poster, T

Download

[T5] Capdevila - Phase 3 LEVEL trial of 177Lu-edotreotide versus everolimus in patients with advanced neuroendocrine tumors of lung or thymic origin (GETNE-T2217)

Published in 2023 Listed under T

Download

[T5] Jimenez - A Phase 2 Open-Label Study of Belzutifan (a HIF-2α Inhibitor) Monotherapy in Patients with Advanced/Metastatic Pheochromocytoma/ Paraganglioma or Pancreatic Neuroendocrine Tumors

Published in 2022 Listed under T

Download

[T5] Poster - Rao - Can NK1 antagonists and COX - 2 inhibitors improve same - day discharge rates following chemoembolization?

Published in 2024 Listed under Poster, T

Download

[T5] Rao - Can NK1 antagonists and COX-2 inhibitors improve same-day discharge rates following chemoembolization?

Published in 2024 Listed under T

Download

[T6] Capdevila - DAREON™-7: Phase 1 trial of BI 764532 (a delta-like ligand 3 [DLL3]-targeting T-cell engager) plus chemotherapy for DLL3+ neuroendocrine carcinomas

Published in 2024 Listed under T

Download

[T6] Halfdanarson - Genetic profiling in the randomized controlled phase 3 COMPOSE trial of 177Lu-edotreotide for well-differentiated aggressive grade 2/3 gastroenteropancreatic neuroendocrine tumors

Published in 2023 Listed under T

Download

[T6] Hope - ACTION-1: A Randomized Phase Ib/3 trial of RYZ101 Compared with SoC in SSTR2+ Well-Differentiated GEP-NET with Progression Following Lu-177 SSA

Published in 2022 Listed under T

Download

[T7] Idrees - Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Patients with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors

Published in 2024 Listed under T

Download

[T7] Lin - Phase 1 Trial of Pb-212-VMT-alpha-NET in Select Metastatic or Inoperable Somatostatin Receptor Positive Tumors

Published in 2023 Listed under T

Download

[T7] Singh - Methodology of the SORENTO Clinical Trial: Assessing Efficacy and Safety of High Exposure Octreotide Subcutaneous Depot in Patients with GEP-NET

Published in 2022 Listed under T

Download

[T8] Chauhan - Phase II Trial Evaluating [177Lu]Lu-DOTA-TATE in Adolescents with Somatostatin Receptor (SSTR)- positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs), Pheochromocytomas and Paragangliomas (PPGLs)

Published in 2022 Listed under T

Download

[T8] Khuong Le - Trial in Progress- Genetic Predisposition Testing Program for Pancreatic Neuroendocrine Neoplasms (PanNENs)

Published in 2024 Listed under T

Download

[T8] Singh - Status of the ongoing SORENTO clinical trial: Assessing efficacy and safety of high-exposure octreotide subcutaneous depot in patients with GEP-NET

Published in 2023 Listed under T

Download

[T9] McGarrah - Phase 1-2 Trial of Vesicular Stomatitis Virus Expressing Human Interferon-β and NIS (VSV-IFNβ-NIS), with Ipilimumab and Nivolumab, in Patients with Neuroendocrine Carcinoma

Published in 2023 Listed under T

Download

[T9] Puranik - PReCedeNT Trial: Phase III Randomised Controlled Trial of PRRT with Lutetium – 177 DOTATATE Plus Chemotherapy Versus PRRT Alone in FDG-avid, Well-Differentiated Gastro-Entero-Pancreatic Neuroendocrine Tumors

Published in 2022 Listed under T

Download